cancers-logo

Journal Browser

Journal Browser

Lung Cancer: Diagnosis and Targeted Therapy

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 10 July 2026 | Viewed by 5

Special Issue Editors


grade E-Mail Website
Guest Editor
Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
Interests: lung cancer; head and neck cancer; translational research; targeted agents; immunotherapy; molecular biology

E-Mail Website
Guest Editor
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
Interests: lung cancer; pulmonary nodule; diagnosis

Special Issue Information

Dear Colleagues,

Lung cancer remains a leading cause of cancer mortality worldwide, yet the field is undergoing a remarkable transformation driven by advances in early detection, molecular characterization, and precision therapeutics. This Special Issue, “Lung Cancer: Diagnosis and Targeted Therapy,” brings together state-of-the-art reviews and emerging evidence highlighting how modern diagnostics and targeted treatment strategies are reshaping outcomes across disease stages and histologies.

This Issue provides an integrated overview of current concepts and future directions in lung cancer care. The diagnostic section covers major developments in screening, imaging, and pathologic and molecular profiling, including next-generation sequencing (NGS), minimal residual disease (MRD) assessment, and the expanding role of liquid biopsy in both early-stage and metastatic settings. Special attention is given to evolving biomarkers in EGFR, ALK, MET, KRAS, HER2, and other oncogenic drivers that guide therapeutic choices and resistance monitoring.

On the therapeutic side, this collection summarizes breakthroughs in targeted therapies, including next-generation tyrosine kinase inhibitors (TKIs), antibody–drug conjugates (ADCs), and rational combination strategies aimed at overcoming resistance. The Issue also discusses the interface between immunotherapy and targeted therapy, optimal sequencing, and emerging modalities such as bispecific antibodies, synthetic lethality approaches, and tumor-agnostic treatments.

Together, the articles in this Special Issue highlight the rapid progress in precision oncology for lung cancer and outline the remaining key challenges, namely early detection, resistance mechanisms, CNS disease control, and equitable access to molecular diagnostics globally. By synthesizing these advances, this Issue aims to provide clinicians and researchers with a clear, updated roadmap for improving patient outcomes through personalized medicine.

Prof. Dr. Myung-Ju Ahn
Prof. Dr. Kyung Jong Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • modern diagnostics
  • screening
  • imaging
  • pathologic and molecular profiling
  • biomarkers
  • targeted therapies
  • next-generation TKIs
  • antibody–drug conjugates (ADCs)
  • drug resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop